Comparative Pharmacology
Head-to-head clinical analysis: ANECTINE versus MIVACRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANECTINE versus MIVACRON.
ANECTINE vs MIVACRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker; mimics acetylcholine at nicotinic receptors at the neuromuscular junction, causing sustained depolarization and receptor desensitization.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
1-1.5 mg/kg IV bolus for intubation; maintenance infusion: 2.5-4.3 mg/min IV; alternatively, 3-4 mg/kg IM for intubation.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
None Documented
None Documented
2-5 minutes (pseudocholinesterase hydrolysis); terminal half-life of succinylmonocholine ~30-60 minutes; clinical duration of apnea determined by rapid initial hydrolysis
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Renal: 10-15% unchanged; hepatic: rapid hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase) to succinylmonocholine and succinic acid; <2% biliary; <2% fecal
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker